ACE OncoCast

Updates on Oncogene-Driven NSCLC from Vienna: Osimertinib resistance

August 14, 2022 ACE Oncology Season 4 Episode 3
Updates on Oncogene-Driven NSCLC from Vienna: Osimertinib resistance
ACE OncoCast
More Info
ACE OncoCast
Updates on Oncogene-Driven NSCLC from Vienna: Osimertinib resistance
Aug 14, 2022 Season 4 Episode 3
ACE Oncology

In this episode, experts explore new data related to EGFR TKI resistance, specifically resistance to osimertinib. Listen to our experts evaluating the real-world data on most common resistance mechanisms to osimertinib and emerging strategies to overcome resistance. 

Show Notes

In this episode, experts explore new data related to EGFR TKI resistance, specifically resistance to osimertinib. Listen to our experts evaluating the real-world data on most common resistance mechanisms to osimertinib and emerging strategies to overcome resistance.